Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) Estimate, Sales $13.77M Beat $11.56M Estimate

Author: Benzinga Newsdesk | March 18, 2024 08:03am
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.91 percent. This is a 62.65 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $13.77 million which beat the analyst consensus estimate of $11.56 million by 19.07 percent. This is a 7.23 percent increase over sales of $12.84 million the same period last year.

Posted In: XGN